Epidemiology of spinal metastases, metastatic epidural spinal cord compression and pathologic vertebral compression fractures in patients with solid tumors: A systematic review

[1]  D. Hinojosa-Gonzalez,et al.  Minimally Invasive versus Open Surgery for Spinal Metastasis: A Systematic Review and Meta-Analysis , 2021, Asian spine journal.

[2]  G. Úrrutia,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. , 2021, Revista espanola de cardiologia.

[3]  A. Carpentier,et al.  Are spine metastasis survival scoring systems outdated and do they underestimate life expectancy? Caution in surgical recommendation guidance. , 2021, Journal of neurosurgery. Spine.

[4]  M. Fehlings,et al.  Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial. , 2021, The Lancet. Oncology.

[5]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[6]  Sidrah Shah,et al.  Management of Metastatic Spinal Cord Compression in Secondary Care: A Practice Reflection from Medway Maritime Hospital, Kent, UK , 2021, Journal of personalized medicine.

[7]  M. Abd-El-Barr,et al.  Gender disparities in clinical presentation, treatment, and outcomes in metastatic spine disease. , 2020, Cancer epidemiology.

[8]  Su Jin Lee,et al.  Bone metastasis and skeletal-related events in patients with solid cancer: A Korean nationwide health insurance database study , 2020, PloS one.

[9]  P. Vermeulen,et al.  Outcome and toxicity of hypofractionated image-guided SABR for spinal oligometastases , 2020, Clinical and translational radiation oncology.

[10]  P. Gerszten,et al.  Single fraction radiosurgery, fractionated radiosurgery, and conventional radiotherapy for spinal oligometastasis (SAFFRON): A systematic review and meta-analysis. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  S. Choi,et al.  The Incidence and Management Trends of Metastatic Spinal Tumors in South Korea: A Nationwide Population-based Study. , 2020, Spine.

[12]  Y. Robinson,et al.  Predictive Scores Underestimate Survival of Patients with Metastatic Spine Disease: A Retrospective Study of 315 Patients in Sweden. , 2020, Spine.

[13]  S. Plaza Canteli,et al.  Metastatic spinal cord compression: Incidence, epidemiology and prognostic factors , 2019, Revista Clínica Española (English Edition).

[14]  Y. Baek,et al.  Incidence of skeletal-related events in patients with breast or prostate cancer-induced bone metastasis or multiple myeloma: A 12-year longitudinal nationwide healthcare database study. , 2019, Cancer epidemiology.

[15]  Z. Vassilev,et al.  Incidence of Skeletal-Related Events in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the US , 2019, Prostate cancer.

[16]  S. Walters,et al.  Quality of life versus length of life considerations in cancer patients: A systematic literature review , 2019, Psycho-oncology.

[17]  H. Zhang,et al.  Prognostic Factors of Ambulatory Status for Patients with Metastatic Spinal Cord Compression: A Systematic Review and Meta-Analysis. , 2018, World neurosurgery.

[18]  Melissa Matz,et al.  Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries , 2018, The Lancet.

[19]  N. Kemeny,et al.  Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[20]  G. Lyman,et al.  Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States , 2018, BMC Cancer.

[21]  L. Thuler,et al.  Impact of Symptomatic Metastatic Spinal Cord Compression on Survival of Patients with Non-Small-Cell Lung Cancer. , 2017, World neurosurgery.

[22]  A. Befeler,et al.  Hepatocellular Carcinoma with Bone Metastases: Incidence, Prognostic Significance, and Management—Single-Center Experience , 2017, Journal of Gastrointestinal Cancer.

[23]  H. Sørensen,et al.  Survival after bone metastasis by primary cancer type: a Danish population-based cohort study , 2017, BMJ Open.

[24]  S. Matsumoto,et al.  Impact of denosumab use on the survival of untreated non-squamous non-small cell lung cancer patients with bone metastases , 2017, Journal of Cancer Research and Clinical Oncology.

[25]  John D. Roberts,et al.  Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial , 2017, JAMA.

[26]  Areerak Phanphaisarn,et al.  Prevalence and Survival Patterns of Patients with Bone Metastasis from Common Cancers in Thailand. , 2016, Asian Pacific journal of cancer prevention : APJCP.

[27]  M. Uder,et al.  Vertebral body fractures of unknown origin in cancer patients receiving MDCT: reporting by radiologists and awareness by clinicians , 2016, SpringerPlus.

[28]  N. James,et al.  Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial. , 2016, JAMA oncology.

[29]  Linda E. Francis,et al.  The longitudinal relationship between quality of life and survival in advanced stage cancer , 2016, Psycho-oncology.

[30]  D. Mitchell,et al.  Burden of illness of bone metastases in prostate cancer patients in Québec, Canada: A population-based analysis. , 2015, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[31]  C. Christiansen,et al.  Hospital use among patients with lung cancer complicated by bone metastases and skeletal- related events: a population-based cohort study in Denmark , 2015, Clinical epidemiology.

[32]  C. Chung,et al.  Nationwide epidemiology and healthcare utilization of spine tumor patients in the adult Korean population, 2009-2012. , 2015, Neuro-oncology practice.

[33]  L. Thuler,et al.  Incidence, associated factors, and survival in metastatic spinal cord compression secondary to lung cancer. , 2015, The spine journal : official journal of the North American Spine Society.

[34]  B. Hutton,et al.  The incidence and clinical impact of bone metastases in non-small cell lung cancer. , 2015, Lung cancer.

[35]  H. Sørensen,et al.  Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish population-based cohort study. , 2014, Lung cancer.

[36]  Z. Weng,et al.  Docetaxel with or without zoledronic acid for castration-resistant prostate cancer , 2014, International Urology and Nephrology.

[37]  C. Mullins,et al.  Skeletal-related events and mortality among older men with advanced prostate cancer. , 2014, Journal of geriatric oncology.

[38]  M. Taphoorn,et al.  Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial , 2014, British Journal of Cancer.

[39]  S. Horie,et al.  Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study. , 2013, Anticancer research.

[40]  Lois Lamerato,et al.  Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems , 2013, Supportive Care in Cancer.

[41]  Z. Weng,et al.  Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases , 2013, Medical Oncology.

[42]  K. Edwards,et al.  Effect of timing of surgery on neurological outcome and survival in metastatic spinal cord compression , 2013, European Spine Journal.

[43]  L. Fallowfield,et al.  Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid , 2012, Clinical Cancer Research.

[44]  R. Mak,et al.  Incidence and treatment patterns in hospitalizations for malignant spinal cord compression in the United States, 1998-2006. , 2011, International journal of radiation oncology, biology, physics.

[45]  H. Sørensen,et al.  Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999–2007) , 2011, Breast Cancer Research and Treatment.

[46]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[47]  J. Vernejoux,et al.  Epidemiology and Treatment Costs of Bone Metastases from Lung Cancer: A French Prospective, Observational, Multicenter Study (GFPC 0601) , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[48]  R. Riesenburger.  A Novel Classification System for Spinal Instability in Neoplastic Disease: An Evidence-Based Approach and Expert Consensus From the Spine Oncology Study Group , 2011 .

[49]  H. Sørensen,et al.  Incidence of bone metastases and skeletal-related events in breast cancer patients: A population-based cohort study in Denmark , 2011, BMC Cancer.

[50]  Henrik Toft Sørensen,et al.  Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). , 2010, The Journal of urology.

[51]  A. Horwich,et al.  Frequency of screening magnetic resonance imaging to detect occult spinal cord compromise and to prevent neurological deficit in metastatic castration-resistant prostate cancer. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

[52]  Ehud Mendel,et al.  A Novel Classification System for Spinal Instability in Neoplastic Disease: An Evidence-Based Approach and Expert Consensus From the Spine Oncology Study Group , 2009, Spine.

[53]  S. Fosså,et al.  A population-based study of spinal metastatic disease in South-East Norway. , 2009, Clinical oncology (Royal College of Radiologists (Great Britain)).

[54]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2008, Journal of clinical epidemiology.

[55]  K. Schulman,et al.  Economic burden of metastatic bone disease in the U.S. , 2007, Cancer.

[56]  Kozo Nakamura,et al.  Incidence and prognostic factors of Japanese breast cancer patients with bone metastasis , 2006, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.

[57]  Mohammed Mohiuddin,et al.  Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial , 2005, The Lancet.

[58]  Y. Ohashi,et al.  Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  P. Sørensen,et al.  Metastatic spinal cord compression , 2005, Acta Neurochirurgica.

[60]  M. Krzakowski,et al.  Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors , 2004, Cancer.

[61]  F. Saad,et al.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. , 2004, Journal of the National Cancer Institute.

[62]  E. Small,et al.  Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  M. Parmar,et al.  A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). , 2003, Journal of the National Cancer Institute.

[64]  W. Mackillop,et al.  A population-based study of malignant spinal cord compression in Ontario. , 2003, Clinical oncology (Royal College of Radiologists (Great Britain)).

[65]  I. Kunkler,et al.  Don't wait for a sensory level--listen to the symptoms: a prospective audit of the delays in diagnosis of malignant cord compression. , 2002, Clinical oncology (Royal College of Radiologists (Great Britain)).

[66]  H. Iguchi,et al.  Increased incidence of bone metastases in hepatocellular carcinoma , 2001, European journal of gastroenterology & hepatology.

[67]  L. Dogliotti,et al.  Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. , 2000, The Journal of urology.

[68]  D. Finkelstein,et al.  Predictors of skeletal complications in patients with metastatic breast carcinoma , 2000, Cancer.

[69]  G. Hortobagyi,et al.  Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  H. Seigler,et al.  Metastatic Melanoma to the Spine Demographics, Risk Factors, and Prognosis in 114 Patients , 1995, Spine.

[71]  J. A. Ortiz Gómez,et al.  The incidence of vertebral body metastases , 1995, International orthopaedics.

[72]  P. Sørensen,et al.  Symptoms and signs in metastatic spinal cord compression: a study of progression from first symptom until diagnosis in 153 patients. , 1994, European journal of cancer.

[73]  DAVID A. WONG,et al.  Spinal Metastases: The Obvious, the Occult, and the Impostors , 1990, Spine.

[74]  P. Sørensen,et al.  Metastatic spinal cord compression. Occurrence, symptoms, clinical presentations and prognosis in 398 patients with spinal cord compression. , 1990, Acta neurochirurgica.

[75]  D. Kuban,et al.  Characteristics of spinal cord compression in adenocarcinoma of prostate. , 1986, Urology.

[76]  J. Moore,et al.  Bone Metastasis , 1982, British Journal of Cancer.

[77]  V. Fornasier,et al.  Metastases to the vertebral column , 1975, Cancer.

[78]  S. Pocock,et al.  Incidence , , 2018 .